Please login to the form below

Not currently logged in


This page shows the latest Rozlytrek news and features for those working in and with pharma, biotech and healthcare.

Immuno-oncology, personalised medicine continues to drive pharma sector

Immuno-oncology, personalised medicine continues to drive pharma sector

Despite rejecting Vitrakvi, NICE said that it was in discussions with Roche for accelerated access to its rival NTRK-inhibitor Rozlytrek (entrectinib), which is currently awaiting EU approval.

Latest news

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Happy Chinese New Year 2020 - The Year of The Rat
A fond farewell to The Year of the Pig...
White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...